Methyldopa (versus unexposed) updated on 03-11-2025

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17246
R72173		 Vaclavik, 2024 Low birth weight during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.74 [1.64;1.86] -/1,043   -/66,393 - 1,043
ref
S14364
R56876		 Orbach, 2013 Low birthweight (< 2500 g) 3rd trimester retrospective cohort (claims database) unexposed, disease free Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 3.77 [2.89;4.94] 84/340   10,001/97,820 10,085 340
ref
Total 2 studies 2.53 [1.19;5.40] 10,085 1,383
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik, 2024Vaclavik, 2024 1.74[1.64; 1.86]-1,04351%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear Orbach, 2013Orbach, 2013 3.77[2.89; 4.94]10,08534049%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 97% 2.53[1.19; 5.40]10,0851,3830.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.53[1.19; 5.40]10,0851,38397%NAVaclavik, 2024 Orbach, 2013 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.53[1.19; 5.40]10,0851,38397%NAVaclavik, 2024 Orbach, 2013 2 Tags Adjustment   - No  - No 1.74[1.63; 1.85]-1,043 -NAVaclavik, 2024 1   - Yes  - Yes 3.77[2.88; 4.93]10,085340 -NAOrbach, 2013 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.53[1.19; 5.40]10,0851,38397%NAVaclavik, 2024 Orbach, 2013 2 All studiesAll studies 2.53[1.19; 5.40]10,0851,38397%NAVaclavik, 2024 Orbach, 2013 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.53[1.19; 5.40]10,0851,38397%NAVaclavik, 2024 Orbach, 2013 20.510.01.0